Pediatrics Archive — Page 26 of 32
-
September 17, 2021
Grant creates center for maternal, pediatric precision therapeutics
Vanderbilt University Medical Center has been awarded a five-year, $6 million grant from the National Institutes of Health to serve as a center of excellence for Maternal and Pediatric Precision in Therapeutics. -
September 15, 2021
Older age, chronic co-morbidities associated with more severe COVID disease in children
Vanderbilt research found that multiple factors are associated with the severity of COVID-19 disease in children, including older age and chronic co-morbidities such as obesity, diabetes and neurologic conditions. -
August 26, 2021
Obese children, young adults at higher risk for thyroid cancer
Children and young adults who are obese are at greater risk for malignant thyroid nodules, according to new study from Monroe Carell Jr. Children’s Hospital at Vanderbilt. -
August 19, 2021
Children, firearms mixing more during pandemic
Researchers at Monroe Carell Jr. Children’s Hospital at Vanderbilt discovered an alarming finding during the height of the pandemic — a marked increase in firearm encounters among children. -
August 4, 2021
Browning to succeed Swan as director of the Pediatric Residency program
After almost two decades as the director of the Pediatric Residency program, Rebecca Swan, MD, professor of Pediatrics, is stepping down to focus on her role as vice chair for Education for the Department of Pediatrics and as assistant dean for Graduate Medical Education. -
July 22, 2021
Change in respiratory care strategies benefits preterm infants
A decade’s worth of data shows that neonatologists are shifting the type of respiratory support they utilize for preterm infants, a move that could lead to improved health outcomes. -
June 3, 2021
Patient of Monroe Carell Jr. Children’s Hospital at Vanderbilt first in world to receive new investigational gene editing therapy
A 9-year-old patient of Monroe Carell Jr. Children’s Hospital at Vanderbilt is the first in the world to receive an investigational gene editing therapy for Methylmalonic Acidemia (MMA), a rare genetic disorder diagnosed at birth.